1 market · 1 product · 2 weeks · ca. 18 hours
Access Diagnostic
25.000DKK
A fixed-scope review of one product in one market: where access breaks, which evidence actually moves the decision, and what to do next.
MARKET ACCESS · HEOR · STRATEGIC ADVISORY
Jasmin
Tiedemann
Evidence alone does
not create access
I connect evidence, patient needs and the decisions that shape access — with clarity, context and human judgement.
Discuss your access challengeStrategist. Lawyer by training. Published author.
BETTER QUESTIONSMORE MEANINGFUL ACCESS
OVERVIEW IN 76 SECONDS
A short introduction to the work
76 seconds on what I do, how I think, and the ways we can work together. It reads with the sound off.
01
Evidence
Ask the right questions
02
Insight
Make complexity meaningful
03
Strategy
Connect value to decisions
04
Access
Keep patients at the centre
A CLEARER WAY FORWARD
From evidence to access
Independent strategic counsel at the intersection of evidence, patient needs and real-world decisions.
THE PERSPECTIVE BEHIND THE WORK
Proving value and creating access
are not the same job
The question is not only whether innovation works.
It is whether our systems recognise what matters to patients.
IDEAS THAT CHALLENGE THE STATUS QUO
Insights & perspectives
REIMBURSEMENT & VALUE
When Reimbursement Systems Fail to Recognize Value
Why demonstrating value is not the same as creating patient access — and what needs to change.
Read the carousel
HEOR & DECISION-MAKING
When Categories Determine Value
What happens when the category decides the value before the evidence is even considered?
Read the carousel
EXPERIENCE WITH A POINT OF VIEW
Evidence-led
Human-centred
14 years across Pharma and MedTech. From global HEOR at Novo Nordisk to international market development at Coloplast across six markets.
I bring a legal foundation, a strategic mindset and a clear conviction: evidence should serve the decisions that improve patient access.
More about JasminWHAT THE WORK LOOKS LIKE
Opening a new MedTech
category in Spain
THE SITUATION
A rigid reimbursement environment where new MedTech categories had no real pathway — formal eligibility existed on paper, but practical access did not.
THE WORK
A multi-year strategy connecting unmet patient need to the decisions that shape access: mapping stakeholders, reframing the value story and building the evidence case step by step.
WHAT CHANGED
From no recognised pathway to a concrete route forward — with the decision-makers, evidence and sequence aligned. The kind of progress that takes persistence, not promises.
Anonymised. Client details stay confidential — the approach is what matters.
WAYS TO WORK TOGETHER
Start where the
decision is
6 hours a month · minimum 3 months
Monthly advisory
18.000DKK / month
A standing senior line for the decisions that do not wait for a project — for teams that own the work and want a second opinion on the hard ones.
1 dossier up to 80 pages · 10 working days · ca. 15 hours
Evidence & submission review
from22.500DKK
An independent read of the evidence you are about to put in front of a payer, a committee or a board — before it goes out.
SPEAKING & KEYNOTES
A voice that challenges
the conversation
Keynotes, expert panels and workshops on evidence, patient access and the human judgement that connects them.
LET’S ASK BETTER QUESTIONS